DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human-Relevant New Approach Methodologies (NAMs)

^

Dynamics Group AG / Schlagwort(e): Sonstiges

DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0,

Advancing Human-Relevant New Approach Methodologies (NAMs)

24.12.2025 / 12:58 CET/CEST

---------------------------------------------------------------------------

DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0,

Advancing Human-Relevant New Approach Methodologies (NAMs)

ZURICH/SCHLIEREN, Switzerland, December 24, 2025 - DiNABIOS AG, a global

leader in human-centric New Approach Methodologies (NAMs) for preclinical

research, today celebrates the U.S. Senate's passage of the FDA

Modernization Act 3.0 (FDAMA 3.0), a milestone in modernizing drug

development by enabling advanced, human-relevant nonclinical testing

methods.

The Act builds on prior modernization efforts by directing the U.S. Food and

Drug Administration (FDA) to establish clear qualification pathways for

NAMs, including advanced cell-based, microphysiological and in silico

systems. Together, these approaches promise improved predictivity, shorter

development timelines, and a meaningful reduction in animal testing.

"FDA Modernization Act 3.0 signals a transformative moment for science and

industry," said Dr. Alexandra Rhoden, CEO of DiNABIOS. "Regulatory alignment

creates opportunity, but adoption will ultimately be driven by scientific

rigor, reproducibility and human relevance, areas where DiNABIOS has made

sustained investments."

Dr. Marcel Grunert, COO of DiNABIOS, added: "This legislation validates the

industry's shift toward scalable, decision-ready NAM platforms. DiNABIOS is

well positioned to support pharmaceutical partners as these methods move

into core decision-making workflows."

Reto Wittwer, Chairman of DiNABIOS, commented: "Modernizing regulatory

frameworks is essential for innovation, efficiency and ethical

responsibility. This moment underscores the importance of companies that

combine scientific excellence with operational readiness - exactly what

DiNABIOS represents."

About DiNABIOS

DiNABIOS is an innovative life science company improving the predictivity

and efficiency of preclinical research from lab to life by integrating

advanced experimental and computational systems grounded in human cell and

tissue biology. For more information visit www.dinabios.com.

Contact

DiNABIOS AG

Wagistrasse 25

8952 Schlieren (Zurich)

Switzerland

contact@dinabios.com

---------------------------------------------------------------------------

Zusatzmaterial zur Meldung:

Datei:

https://eqs-cockpit.com/c/fncls.ssp?u=850673a75ba293d448f68bef14716148

Dateibeschreibung: Media Release DiNABIOS_FDA Modernization Act_2025

---------------------------------------------------------------------------

Ende der Medienmitteilungen

Originalinhalt anzeigen:

https://eqs-news.com/?origin_id=be391ca6-e0be-11f0-be29-0694d9af22cf&lang=de

---------------------------------------------------------------------------

2251462 24.12.2025 CET/CEST

°